logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Merrimack Pharmaceuticals, Inc.


USPTO Granted Patents = 54

% Expired Patents = 55.6



Trademarks = 3

Forward Citations = 447

Loading Chart...
Loading Chart...

81 inventors (with patents filed for the assignee):

goldMedal Ulrik Bjerl Nielsen (19 out of 26 patents)

silverMedal Birgit Schoeberl (13 out of 18 patents)

bronzeMedal Michael Feldhaus (10 out of 30 patents)

4.  Neeraj Kohli (10 out of 12 patents)

5.  Alexey Alexandrovich Lugovskoy (9 out of 52 patents)

6.  Jonathan Basil Fitzgerald (9 out of 19 patents)

7.  Thomas Joseph Wickham (9 out of 15 patents)

8.  Brian Harms (8 out of 13 patents)

9.  Dmitri B Kirpotin (8 out of 47 patents)

10.  Daryl C Drummond (7 out of 38 patents)

11.  Matthew D Onsum (7 out of 17 patents)

12.  Jeffrey David Kearns (7 out of 7 patents)

13.  Victor Mandla Moyo (7 out of 44 patents)

14.  Eric Krauland (6 out of 20 patents)

15.  Bryan Linggi (6 out of 11 patents)


Core Competencies:
Bi-Specific Fusion Proteins
Anti-TNFR2 Antibodies
EGFR Antibodies
Biomarkers
Nucleic Acid Delivery
Combination Therapy
Liposomal Drug Delivery
Cancer Therapy
Immunoliposomes
Cell-Based Screening
ERBB3 Inhibitors
Human Serum Albumin

54 patents:

1. 12715937 - Bi-Specific Fusion Proteins (2026-08-25),
2. 12698347 - Bi-Specific Fusion Proteins (2026-08-04),
3. 12435151 - Anti-TNFR2 antibodies and uses thereof (2025-10-07),
4. 10570119 - Inhibiting ataxia telangiectasia and Rad3-related protein (ATR) (2020-02-25),
5. 10273304 - Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies (2019-04-30),
6. 10184006 - Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors (2019-01-22),
7. 10087464 - Compositions and methods for delivering nucleic acid to a cell (2018-10-02),
8. 10072299 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-09-11),
9. 9982060 - Bi-specific fusion proteins (2018-05-29),
10. 9968694 - Compositions and methods for non-invasive imaging (2018-05-15),
11. 9938346 - Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies (2018-04-10),
12. 9920131 - Dosage and administration of anti-EGFR therapeutics (2018-03-20),
13. 9913901 - Combination therapy for treating HER2-positive cancers (2018-03-13),
14. 9902999 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-27),
15. 9885087 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-06),
Company Overview
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, MA, specializing in the development of innovative therapies for cancer treatment. The company focuses on advanced technologies such as bi-specific fusion proteins and anti-TNFR2 antibodies, aiming to enhance therapeutic efficacy and patient outcomes. Merrimack's research encompasses key areas including nucleic acid delivery, combination therapies, and liposomal drug delivery, positioning it at the forefront of cancer therapy advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

54 Patents

#48 in Cambridge, MA

#372 in Massachusetts

#6,560 in US

#13,126 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Merrimack Pharmaceuticals, Inc.

Forward Citations = 447

81 inventors:

goldMedal Ulrik Bjerl Nielsen (19 out of 26 patents)

silverMedal Birgit Schoeberl (13 out of 18 patents)

bronzeMedal Michael Feldhaus (10 out of 30 patents)

4.  Neeraj Kohli (10 out of 12 patents)

5.  Alexey Alexandrovich Lugovskoy (9 out of 52 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merrimack Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/merrimack-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…